The UK Health Security Agency has issued an important reminder that these medications don't work for flu and colds ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

Antibiotics save lives every day, but some of these powerful medications come with serious risks that you need to understand before taking them. While your doctor has prescribed them for good reason, ...

Nitazoxanide is a new thiazolide antiparasitic agent that has excellent activity in treating both interstitial protozoal and helminthic infections. [3,17] Pharmacokinetic studies in humans have shown ...

Data presented at Digestive Disease Week (DDW) 2025 demonstrated safety and treatment success in patients treated for recurrent C. Diff infection with REBYOTA administered by colonoscopy Data also ...

FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA @ Home ...

Vowst (fecal microbiota spores, live-brpk) can cause side effects that range from mild to serious. More common side effects include tiredness and constipation. If side effects from Vowst become ...

Vowst (fecal microbiota spores, live-brpk) is a brand-name oral capsule that’s prescribed to help prevent Clostridioides difficile (C. diff) infection returning after antibiotic treatment in certain ...

The same technology that saved millions of lives during the COVID-19 pandemic appears to hold promise against another scourge of infectious disease, according to new research from the University of ...

St. Louis-based Washington University School of Medicine researchers found that fidaxomicin, a treatment for Clostridioides difficile infection, has increased in use but “remains underutilized.” The ...